Video

Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma

Jeffrey S. Weber, MD, PhD, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses biomarker research in the CheckMate-238 trial looking at patients with resected stage III/IV melanoma.

For the first time, researchers collected biomarker data from a significant portion of patients from the CheckMate-238 trial. Researchers looked at 3 tumor-related biomarkers: tumor mutational burden (TMB) by whole-exome sequencing, interferon-gamma—induced genes by shotgun sequencing, and CD8+ T-cell infiltrate by histochemistry, explains Weber.

Additionally, for the first time there was a peripheral blood marker consisting of monocytic myeloid-derived suppressor cells (MDSC) in the peripheral blood by flow cytometry, according to Weber. The tumor markers are above the median for peripheral blood suppressive marker, showing a clear association with outcome for the nivolumab (Opdivo) and ipilimumab (Yervoy) arms, says Weber. The most potent biomarkers with the best hazard ratios were the interferon-gamma—induced genes and TMB.

In combinations of typically independent biomarkers, elevation in TMB above the median, elevation of the interferon-gamma—induced genes above the median, or depression of MDSC resulted in a better hazard ratio for outcome, Weber concludes.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD